Tag - KPTI

Executive Moves

Karyopharm appoints Lori Macomber as EVP, CFO, and treasurer

Karyopharm Therapeutics (NASDAQ: KPTI) has announced the appointment of Lori Macomber as executive vice president (EVP), chief financial officer (CFO), and treasurer, effective January 3, 2025. Ms. Macomber, who will be...

January 2, 2025

Developments

Karyopharm Therapeutics doses first glioblastoma patient in Phase 1/2 selinexor study

Karyopharm Therapeutics (NASDAQ:KPTI) dosed the first patient in a Phase 1/2 clinical study evaluating oral selinexor in patients with newly diagnosed or recurrent glioblastoma (GBM). This global study is expected to...

June 9, 2020

Developments

Karyopharm Therapeutics doses first COVID-19 patient in selinexor study

Karyopharm Therapeutics (NASDAQ:KPTI) dosed the first patient in a Phase 2 clinical study evaluating low-dose oral selinexor in hospitalized patients with severe COVID-19. Selinexor is designed to block XPO1, a...

April 20, 2020

Developments

Karyopharm’s Phase 3 multiple myeloma trial meets primary endpoint

Karyopharm Therapeutics (NASDAQ:KPTI) reported positive topline results from its Phase 3 BOSTON study in patients with multiple myeloma who have received one-to-three prior lines of therapy. The study evaluated once...

March 2, 2020

Tag - KPTI

Karyopharm appoints Lori Macomber as EVP, CFO, and treasurer

Karyopharm Therapeutics doses first glioblastoma patient in Phase 1/2 selinexor study

Karyopharm Therapeutics doses first COVID-19 patient in selinexor study

Karyopharm’s Phase 3 multiple myeloma trial meets primary endpoint

General

More